Suppr超能文献

糖化血红蛋白变异性作为1型糖尿病微血管病变风险指标的作用

The Effect of HbA Variability as a Risk Measure for Microangiopathy in Type 1 Diabetes Mellitus.

作者信息

Romero-Aroca Pedro, Navarro-Gil Raul, Feliu Albert, Valls Aida, Moreno Antonio, Baget-Bernaldiz Marc

机构信息

Ophthalmology Service, University Hospital Sant Joan, Institut de Investigacio Sanitaria Pere Virgili (IISPV), Universitat Rovira & Virgili, 43204 Reus, Spain.

Pediatric Service, University Hospital Sant Joan, Institut de Investigacio Sanitaria Pere Virgili (IISPV), Universitat Rovira & Virgili, 43204 Reus, Spain.

出版信息

Diagnostics (Basel). 2021 Jun 24;11(7):1151. doi: 10.3390/diagnostics11071151.

Abstract

BACKGROUND

To measure the relationship between variability in HbA and microalbuminuria (MA) and diabetic retinopathy (DR) in the long term.

METHODS

A prospective case-series study, was conducted on 366 Type 1 Diabetes Mellitus patients with normoalbuminuria and without diabetic retinopathy at inclusion. The cohort was followed for a period of 12 years. The Cox survival analysis was used for the multivariate statistical study. The effect of variability in microangiopathy (retinopathy and nephropathy) was evaluated by calculating the standard deviation of HbA (SD-HbA), the coefficient of variation of HbA (CV-HbA), average real variability (ARV-HbA) and variability irrespective of the mean (VIM-HbA) adjusted for the other known variables.

RESULTS

A total of 106 patients developed diabetic retinopathy (29%) and 73 microalbuminuria (19.9%). Overt diabetic nephropathy, by our definition, affected only five patients (1.36%). Statistical results show that the current age, mean HbA, SD-HbA and ARV-HbA are significant in the development of diabetic retinopathy. Microalbuminuria was significant for current age, mean HbA, CV-HbA and ARV-HbA.

CONCLUSIONS

By measuring the variability in HbA, we can use SD-HbA and ARV-HbA as possible targets for judging which patients are at risk of developing DR and MA, and CV-HbA as the target for severe DR.

摘要

背景

长期测量糖化血红蛋白(HbA)变异性与微量白蛋白尿(MA)及糖尿病视网膜病变(DR)之间的关系。

方法

对366例入选时尿白蛋白正常且无糖尿病视网膜病变的1型糖尿病患者进行前瞻性病例系列研究。该队列随访12年。采用Cox生存分析进行多变量统计研究。通过计算校正其他已知变量后的糖化血红蛋白标准差(SD-HbA)、糖化血红蛋白变异系数(CV-HbA)、平均实际变异性(ARV-HbA)和不考虑均值的变异性(VIM-HbA),评估微血管病变(视网膜病变和肾病)变异性的影响。

结果

共有106例患者发生糖尿病视网膜病变(29%),73例发生微量白蛋白尿(19.9%)。按照我们的定义,显性糖尿病肾病仅影响5例患者(1.36%)。统计结果表明,当前年龄、平均HbA、SD-HbA和ARV-HbA在糖尿病视网膜病变的发生中具有显著性。微量白蛋白尿在当前年龄、平均HbA、CV-HbA和ARV-HbA方面具有显著性。

结论

通过测量HbA变异性,我们可以将SD-HbA和ARV-HbA作为判断哪些患者有发生DR和MA风险的可能指标,将CV-HbA作为严重DR的指标。

相似文献

1
The Effect of HbA Variability as a Risk Measure for Microangiopathy in Type 1 Diabetes Mellitus.
Diagnostics (Basel). 2021 Jun 24;11(7):1151. doi: 10.3390/diagnostics11071151.
9
Cardiovascular Autonomic Neuropathy Predicts Higher HbA1c Variability in Subjects with Type 2 Diabetes Mellitus.
Diabetes Metab J. 2018 Dec;42(6):496-512. doi: 10.4093/dmj.2018.0026. Epub 2018 Sep 28.

本文引用的文献

1
6. Glycemic Targets: .
Diabetes Care. 2020 Jan;43(Suppl 1):S66-S76. doi: 10.2337/dc20-S006.
4
2. Classification and Diagnosis of Diabetes: .
Diabetes Care. 2018 Jan;41(Suppl 1):S13-S27. doi: 10.2337/dc18-S002.
5
Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis.
Lancet Glob Health. 2017 Dec;5(12):e1221-e1234. doi: 10.1016/S2214-109X(17)30393-5. Epub 2017 Oct 11.
7
Differences in incidence of diabetic retinopathy between type 1 and 2 diabetes mellitus: a nine-year follow-up study.
Br J Ophthalmol. 2017 Oct;101(10):1346-1351. doi: 10.1136/bjophthalmol-2016-310063. Epub 2017 Mar 7.
8
Changes observed in diabetic retinopathy: eight-year follow-up of a Spanish population.
Br J Ophthalmol. 2016 Oct;100(10):1366-71. doi: 10.1136/bjophthalmol-2015-307689. Epub 2016 Jan 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验